CervoMed (CRVO) Stock Forecast, Price Target & Predictions
CRVO Stock Forecast
CervoMed stock forecast is as follows: an average price target of $16.32 (represents a 631.84% upside from CRVO’s last price of $2.23) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CRVO Price Target
The average price target for CervoMed (CRVO) is $16.32 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $16.32 to $16.32. This represents a potential 631.84% upside from CRVO's last price of $2.23.
CRVO Analyst Ratings
According to 4 Wall Street analysts, CervoMed's rating consensus is 'Buy'. The analyst rating breakdown for CRVO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 1 'Hold' (25.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
CervoMed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 18, 2024 | Danill Gataulin | Loop Capital Markets | $16.32 | $4.79 | 240.71% | 631.84% |
| Sep 18, 2024 | Daniil Gataulin | Chardan Capital | $16.32 | $4.79 | 240.71% | 631.84% |
| Apr 08, 2024 | Sumant Kulkarni | Canaccord Genuity | $19.29 | $6.08 | 217.27% | 765.02% |
The latest CervoMed stock forecast, released on Sep 18, 2024 by Danill Gataulin from Loop Capital Markets, set a price target of $16.32, which represents a 240.71% increase from the stock price at the time of the forecast ($4.79), and a 631.84% increase from CRVO last price ($2.23).
CervoMed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 3 |
| Avg Price Target | - | $16.32 | $17.31 |
| Last Closing Price | $2.23 | $2.23 | $2.23 |
| Upside/Downside | -100.00% | 631.84% | 676.23% |
In the current month, the average price target of CervoMed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CervoMed's last price of $2.23. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 17, 2024 | H.C. Wainwright | Buy | Neutral | Downgrade |
| Dec 11, 2024 | Morgan Stanley | Overweight | Underweight | Downgrade |
| Sep 18, 2024 | Chardan Capital | Buy | Initialise | |
| Jul 26, 2024 | Morgan Stanley | Overweight | Initialise | |
| Apr 08, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Aug 16, 2022 | H.C. Wainwright | Buy | Upgrade |
CervoMed's last stock rating was published by H.C. Wainwright on Dec 17, 2024. The company Downgrade its CRVO rating from "Buy" to "Neutral".
CervoMed Financial Forecast
CervoMed Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
CervoMed's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CRVO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
CervoMed EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict CRVO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than CervoMed's previous annual EBITDA (undefined) of $NaN.
CervoMed Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
CervoMed's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRVO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
CervoMed SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
CervoMed's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CRVO last annual SG&A of $NaN (undefined).
CervoMed EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, CervoMed's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRVO previous annual EPS of $NaN (undefined).